Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
The U.S. orphan drug market is projected to exceed $200 billion by 2031, driven by innovation in oncology and genetic disorders. More than 1,400 FDA-designated orphan drugs are in development or marketed, with over 800 currently in clinical trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07372690 |
Goal Attainment Scale in Transplantation |
RECRUITING | NA |
| NCT07065344 |
A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region |
NOT_YET_RECRUITING | |
| NCT06840756 |
Effects of Donor-recipient Sex-matched Blood Transfusion on Patient Outcomes |
RECRUITING | PHASE4 |
| NCT06007794 |
Correlation Between Ultrasound-assessed Quadriceps Muscle Mass and Baseline Whole-body Densitometry Muscle Index in the Post-cancer Population (JUMP Research II) |
RECRUITING | NA |
| NCT05763186 |
The Right Amount of Purge Useful for Blood Sampling on PiccLine (PiccLine) |
RECRUITING | NA |
| NCT05242341 |
Increase Understanding and Safety of Treatment |
UNKNOWN | NA |
| NCT04931329 |
Onco-haematology Vigilance Card |
UNKNOWN | |
| NCT04618848 |
Performance Evaluation Study |
UNKNOWN | |
| NCT03595501 |
Analytical and Clinical Performance Testing Plan |
COMPLETED | |
| NCT02835937 |
Red Blood Cell Transfusion in the Ambulatory Setting: Impact on Home Functional Status |
COMPLETED | NA |
